Segment Data (Tables)

6 Months Ended

Jun. 25, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:

	Three Months Ended				Six Months Ended
	June 25, 2021		June 26, 2020		June 25, 2021		June 26, 2020
Net sales:
Specialty Brands	$	381.5	$	522.8	$	789.9	$	1,013.4
Specialty Generics	164.9		178.1		314.5		353.3
Segment net sales	546.4		700.9		1,104.4		1,366.7
Medicaid lawsuit (Note 12)	—		(534.4)		—		(534.4)
Net sales	$	546.4	$	166.5	$	1,104.4	$	832.3
Operating income (loss):
Specialty Brands	$	186.6	$	252.7	$	398.7	$	473.2
Specialty Generics	26.9		49.2		58.6		112.4
Segment operating income	213.5		301.9		457.3		585.6
Unallocated amounts:
Corporate and unallocated expenses (1)	(25.7)		(52.7)		(48.3)		(110.2)
Depreciation and amortization	(168.1)		(216.3)		(337.7)		(439.4)
Share-based compensation	(2.4)		(6.6)		(6.0)		(13.3)
Restructuring charges, net	(6.1)		(14.4)		(6.5)		(12.6)
Non-restructuring impairment charges	—		(63.5)		(64.5)		(63.5)
Separation costs (2)	(0.3)		(20.7)		(0.9)		(42.0)
R&D upfront payment (3)	—		(5.0)		—		(5.0)
Opioid-related litigation settlement (loss) gain (4)	—		(8.5)		—		8.3
Medicaid lawsuit (Note 12)	—		(639.7)		—		(639.7)
Operating income (loss)	$	10.9	$	(725.5)	$	(6.6)	$	(731.8)

(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(2)Represents costs included in SG&A expenses, primarily related to professional fees and costs incurred in preparation for the Chapter 11 proceedings. As of the Petition Date, professional fees directly related to the Chapter 11 proceedings that were previously reflected as separation costs are being classified on a go-forward basis as reorganization items, net.

(3)Represents R&D expense incurred related to an upfront payment made to acquire product rights in Japan for terlipressin.

(4)Represents the change in the Settlement Warrants' fair value. Refer to Note 12 for further information.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:

	Three Months Ended				Six Months Ended
	June 25, 2021		June 26, 2020		June 25, 2021		June 26, 2020
Acthar Gel	$	151.5	$	213.7	$	280.5	$	381.3
INOmax	105.9		154.9		239.9		296.6
Ofirmev	6.5		52.4		19.3		127.3
Therakos	68.5		47.8		135.3		111.5
Amitiza (1)	44.8		49.4		106.2		90.5
Other	4.3		4.6		8.7		6.2
Specialty Brands	381.5		522.8		789.9		1,013.4
Hydrocodone (API) and hydrocodone-containing tablets	20.5		25.4		43.8		51.9
Oxycodone (API) and oxycodone-containing tablets	17.1		15.0		34.3		31.9
Acetaminophen (API)	51.7		55.5		97.2		99.6
Other controlled substances	69.0		77.8		127.1		161.4
Other	6.6		4.4		12.1		8.5
Specialty Generics	164.9		178.1		314.5		353.3
Segment net sales	546.4		700.9		1,104.4		1,366.7
Medicaid lawsuit (Note 12)	—		(534.4)		—		(534.4)
Net sales	$	546.4	$	166.5	$	1,104.4	$	832.3

(1)Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.